nivolumab plus ipilimumab
Double Checkpoint Inhibitors Plus TKI Improves Control of RCC
In patients with advanced renal cell carcinoma, the addition of the tyrosine kinase inhibitor cabozantinib ...
OCTOBER 3, 2022
Nivolumab-Ipilimumab Combo Approved to Treat Previously Treated HCC
The FDA granted accelerated approval for the use of nivolumab plus ipilimumab to treat hepatocellular carcinoma in ...
MARCH 12, 2020
Opdivo-Yervoy Granted Priority Review for Intermediate-, Poor-Risk Advanced RCC
The FDA has granted priority review status to a supplemental New Drug Application for nivolumab (Opdivo, ...
DECEMBER 18, 2017
Nivolumab-Ipilimumab Combo Beneficial in Advanced RCC
The combination of nivolumab and ipilimumab improved OS over sunitinib in patients with previously untreated ...
SEPTEMBER 20, 2017
Load more